Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $56.57.

Several research analysts have recently commented on AGIO shares. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th.

Agios Pharmaceuticals Stock Up 1.4 %

AGIO stock opened at $30.84 on Friday. Agios Pharmaceuticals has a 52-week low of $27.14 and a 52-week high of $62.58. The business has a fifty day moving average of $33.21 and a two-hundred day moving average of $40.97. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 2.72 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, sell-side analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $33,000. GF Fund Management CO. LTD. purchased a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $39,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $53,000. Sterling Capital Management LLC lifted its stake in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 1,587 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.